Omnipod® for children
We understand that caring for a child with type 1 diabetes isn’t easy. You want an insulin delivery method that can meet your child’s evolving health needs, while also granting them the freedom of being a child.
Omnipod works with you and your little one to do just that. With no multiple daily injections and no tubes, Pod Therapy is insulin pump therapy, simplified. It’s a system you can trust.
Omnipod 5 is our automated insulin delivery (AID) system. It’s the only tubeless AID system that works with the leading sensor brands, creating a fully waterproof† and fully wearable AID system compatible with the Dexcom G7 Sensor or FreeStyle Libre 2 Plus Sensor.
With no finger prick testing‡ and no need to disconnect for daily activities, your child is free to be free without interruptions. Meanwhile, you can share the load with a system that’s always adjusting* so you don’t have to.
The benefits of Omnipod
Freedom to play, freedom to learn, freedom to be a child!
No multiple daily injections, and no tubes: Each tubeless, wearable Pod delivers insulin for up to three days (72 hours). Your child can go to a dance class or play video games with fewer interruptions.
Waterproof†: The Pod can be worn while swimming, bathing, or showering.
Discreet: Small enough to be worn under clothing, with no tubes hanging loose.
Accurate: Precise dosing with 0.05 unit increments allowing for precise (or customizable) mealtime dosing.
All of this could mean less diabetes disruption for your family, greater peace of mind for you - and more independence for your little one.
How does the Omnipod work?
Pod Therapy from Omnipod is a tubeless insulin delivery system designed for people with type 1 diabetes.
Pod Therapy replaces the need for multiple daily injections by delivering small, customisable doses of insulin to your child’s body throughout the day, through a wearable and waterproof† patch pump called a Pod.
Omnipod differs from other insulin pump products with its innovative, compact, and tubeless design, made to fit around you and your child’s busy lives.
Meet our Tubeless, wearable Omnipod® Lineup.
Omnipod 5 Automated Insulin Delivery System
Omnipod 5 is a tubeless automated insulin delivery system that works with the leading sensor brands*.
Compatible with the Dexcom G7 Sensor and the FreeStyle Libre 2 Plus Sensor, Omnipod 5 makes automated insulin adjustments every five minutes based on CGM readings, to help keep your child in range1,2.
Omnipod DASH® Insulin Management System
Simplify Life™ with Omnipod DASH. Place the Pod on your child’s body almost anywhere you would inject insulin for up to three days (72 hours) of precise, continuous insulin delivery.
Discreetly and conveniently adjust your child’s insulin doses with a few finger taps wherever you are, without any insulin pump tubing.
Speak to your Healthcare provider to find out more!
* Requires Dexcom G7 or FreeStyle Libre 2 Plus sensor. Bolus for meals and corrections are still needed.
‡At start-up, the Pod and Controller / Personal Diabetes Manager must be adjacent and touching. During normal operation, the Personal Diabetes Manager must be within 1.5 metres of the Pod.
1. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in adults/adolescents as measured by CGM: ST = 64.7%, 3-mo Omnipod 5 = 73.9%, P<0.0001. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in children as measured by CGM: ST = 52.5%, 3-mo Omnipod 5 = 68.0%, P<0.0001. Mean HbA1c: ST vs. Omnipod 5 use in adults/adolescents (14-70 yrs) and children (6-13.9 yrs), respectively (7.16% vs 6.78% or 55 mmol/mol vs. 51 mmol/mol, P<0.0001; 7.67% vs 6.99% or 60mmol/mol vs 53 mmol/mol), P<0.0001). Mean time in hypoglycaemic range in adults/adolescents (<3.9 mmol/L or <70mg/dL as measured by CGM) as measured by CGM: ST = 1.89%, 3-mo Omnipod 5 = 1.32%, P<0.0001
2. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 57.2% vs 68.1%, P<0.0001. Mean time in hypoglycaemic range (<3.9mmol/L or <70mg/dL as measured by CGM) ST = 3.43% vs Omnipod 5: 2.46%, P<0.0001.